New Delhi : The combination of casirivimab and imdevimab (two monoclonal antibody treatments) keeps high-risk patients away from the hospital when infected with mild to moderate...
Recovery trial results show that Regeneron’s intra-trial antibody combination therapy reduces the risk of death in hospitalized patients with severe COVID-19 seronegative. Results from a randomized...
Recent Comments